Tonix Pharmaceuticals Holding (TNXP) Gross Profit (2023 - 2026)

Tonix Pharmaceuticals Holding's Gross Profit history runs 4 years deep, the most recent figure standing at $5.3 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 256.66% year-over-year to $5.3 million in Q1 2026; TTM through Mar 2026 was $10.3 million, a 243.5% increase from a year earlier, with the FY2025 full-year figure at $6.5 million, up 177.67% from the prior year.
• Gross Profit advanced to $5.3 million in Q1 2026 per TNXP's latest filing, from $4.3 million in the prior quarter.
• Across five years, Gross Profit topped out at $5.3 million in Q1 2026 and bottomed at -$1.3 million in Q2 2025.
• The 4-year median for Gross Profit is $1.4 million (2023), against an average of $1.6 million.
• Across the five-year window, Gross Profit retreated 21.55% in 2024 and soared 256.66% in 2026, its largest moves.
• Year by year, Gross Profit stood at $1.4 million in 2023, then slipped by 0.92% to $1.4 million in 2024, then jumped by 209.65% to $4.3 million in 2025, then increased by 22.35% to $5.3 million in 2026.
• Per Business Quant, the three latest TNXP Gross Profit figures stand at $5.3 million (Q1 2026), $4.3 million (Q4 2025), and $1.9 million (Q3 2025).